What question did this study set out to answer?

The aim of the research is to assess the effectiveness and safety of lecanemab in the Chinese Alzheimer's disease population.

March 15, 2026Open Access

Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real‐world study

Key Points

The aim of the research is to assess the effectiveness and safety of lecanemab in the Chinese Alzheimer's disease population.
Multicenter real-world study
Evaluation of lecanemab efficacy and safety
Measure plasma p-tau217 levels as a biomarker
Lecanemab was effective in treating Alzheimer's disease in the observed population
Lecanemab was well tolerated by patients
Plasma p-tau217 shows potential as a treatment-response biomarker

Abstract

Lecanemab was effective and well tolerated in real-world Chinese patients. Plasma p‑tau217 may serve as a sensitive, minimally invasive treatment-response biomarker.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper